AM679

AM679 is a potent, selective 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC₅₀ of 2 nM in a human FLAP membrane binding assay. AM679 markedly reduces the respiratory syncytial virus-driven ocular pathology as well as the synthesis of cysteinyl leukotrienes (CysLTs) in the eye^[1]. In Vitro: AM679 is a potent, selective inhibitor of FLAP, as demonstrated in an in vitro human FLAP membrane binding assay with IC₅₀ of 2 nM and when assayed as an inhibitor of ex vivo ionophore-challenged mouse and human blood LTB4 synthesis with IC₅₀s of 55 nM and 154 nM, respectively^[1].
AM679 is a potent and selective FLAP inhibitor with IC₅₀s of 2.2 nM/0.6 nM/154 nM for FLAP binding/hLA/hWB respectively^[2]. In Vivo: AM679 shows potent inhibition of leukotrienes in human blood and in a rodent bronchoalvelolar lavage challenge model^[2].